Efficacy of drugs in controlling microalbuminuria of diabetic nephropathy

A. Sudhakar¹, Sujatha Pasula²*, G. B. Simpson¹

INTRODUCTION

The number of cases of diabetes worldwide in 2000 among adults more than 20 years of age is estimated to be 171 million. Prevalence is estimated to be 0.19% in population less than 20 years, 8.6% in those above 20 years and reaching 20.1% in those more than 65 years.¹ Globally, diabetes prevalence is similar in men and women, but it is slightly higher in men 60 years of age and in women at older ages. By 2030, it is estimated that the number of people with diabetes 64 years of age will be 82 million in developing countries and 48 million in developed countries.¹ India tops the list with 31.7 million people with diabetes and is estimated to grow up to 79.4 million diabetics by 2030.¹

Diabetes mellitus (DM) remains the leading cause of end-stage renal disease, the world over. In persons with type 2 DM, hypertension and increased urinary albumin excretion are features of diabetic nephropathy. Increased urinary protein excretion is the earliest clinical finding of diabetic nephropathy. Diabetic patients with this complication are at increased risk for cardiovascular events and, if untreated, have a relentless decline in renal function leading to renal failure.

Angiotensin converting enzyme (ACE) inhibitors competitively block renin angiotensin system, decrease glomerular capillary pressure and prevent progression of microalbuminuria to overt proteinuria.¹ A similar beneficial effect of angiotensin II receptor blockers (ARB) in regression of microalbuminuria to overt proteinuria

ABSTRACT

Background: Beneficial effect in reducing microalbuminuria of diabetic nephropathy with angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blockers (ARB) is proven. This study has directly compared the renoprotective effects of ARB and ACE inhibitors in persons with type-2 diabetes.

Methods: In this prospective, double-blind, controlled trial, 100 patients with type 2 diabetes mellitus were chosen and randomly assigned to either receive ACE inhibitor (ramipril 5 mg, 50 patients) or ARB (losartan 50 mg, 50 patients). The endpoint was a reduction in 24 hrs urine microalbuminuria after a period of 3 months treatment.

Results: At the end of 3 months treatment, the mean reduction of 24 hrs urine microalbuminuria in the ramipril group was 25 mg as compared to 38 mg in the losartan group; (t value=1.11, p=0.27). There was no statistical difference in the mean reduction when compared between the two groups. Significant reduction of blood pressure especially systolic blood pressure was noted in the losartan group as compared to those who received ramipril.

Conclusion: Losartan was not inferior to ramipril in providing renoprotection in subjects with type 2 diabetes and early nephropathy. Losartan showed a significant reduction in systolic blood pressure, though not much reduction was seen with ramipril. Despite this, both drugs have shown a reduction in microalbuminuria, which supports the fact that reduction in microalbuminuria is independent of the antihypertensive action of ramipril or losartan.

Keywords: Microalbuminuria, Diabetic nephropathy, Angiotensin converting enzyme inhibitor, Angiotensin II receptor blocker

¹Department of Pharmacology, Katuri Medical College and Hospital, Chinakondrupadu, Guntur - 522 019, Andhra Pradesh, India, ²Global Hospitals, Saroornagar, L. B. Nagar, Hyderabad - 500 035, Andhra Pradesh, India

© 2014 Sudhakar A et al. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
has been seen in various studies. There is a need for head-to-head comparison of ACE inhibitors and ARB in diabetic nephropathy.

The study is to evaluate and compare the efficacy of ACE Inhibitor versus ARB in controlling microalbuminuria of diabetic nephropathy.

**METHODS**

It is prospective, randomized, double-blind study with 100 patients of type 2 DM with evidence of microalbuminuria (urine albumin excretion rate of 30-300 mg/24 hrs) were chosen for the study. They were randomized into two groups of 50 each (Group A and Group B) in a double blind fashion. Group A patients received ACE inhibitor (ramipril 5 mg), Group B patients received ARB (losartan 50 mg) and the mean age group of 45-60 years (both males and females). Type I DM, overt proteinuria, history of hypertension, history of coronary heart disease, non-diabetic renal disease were excluded.

Subjects were followed up over a period of 3 months from the day of start of treatment. Albumin in 24 hrs urine was tested by the radio immuno-assay method - at the start of the study and at the end of 3 months of treatment with either an ACE inhibitor or an ARB. Diabetes was controlled with diet, oral hypoglycemic drugs or insulin.

At the end of 3 months, the collected data were analyzed for:
1. Reduced/absent microalbuminuria or
2. Persistent microalbuminuria (microalbuminuria of same or increased amount as compared to before the start of treatment).

**RESULTS**

All the cases were randomized into either group (ACE inhibitor or ARB) and studied at the beginning and at the end of 3 months of treatment.

**DISCUSSION**

A decline in the glomerular filtration rate is a key determinant of end-stage renal disease. Preventing (or delaying) the development of microalbuminuria is the key treatment goal for renoprotection. Recent clinical trials suggest that inhibition of the renin angiotensin system may actually prevent nephropathy. The posthoc analyses of the reduction in hypertension in the Heart Outcomes Prevention Evaluation Study and in the losartan intervention for the end point study, found a lower incidence of overt nephropathy in subjects with type 2 diabetes who received therapy that inhibited the renin angiotensin system than in controls.

Trials have supported the clinical equivalence of ARB and ACE inhibitors in delaying the progression of nephropathy in type 2 diabetes and in conditions that place them at high risk for cardiovascular events. There has been a clinical study that has directly compared the effect of an ARB (losartan) with that of an ACE inhibitor (ramipril) in subjects with type 2 diabetes and early nephropathy.

The present study is a similar study making head-to-head comparison of ACE inhibitor (ramipril) and ARB (losartan) in the regression of microalbuminuria in type 2 diabetics. The study has shown that both the drugs – ramipril and losartan reduce urinary albumin excretion (Table 1 & Figure 1) and within the group, the reduction in microalbuminuria is considerable and significant. However, the difference in reduction of microalbuminuria when compared between the two groups is statistically insignificant (Table 2).

Further, the study shows that losartan had better reduction in systolic blood pressure, as compared to the reduction seen with ramipril. (Table 2, 3 & Figure 2) though not significant difference was seen in the reduction of diastolic blood pressure (Table 2, 4 & Figure 3). Despite this difference on blood pressure, both the drugs have shown a reduction in microalbuminuria which supports the fact that reduction in microalbuminuria is independent of the antihypertensive action of the ramipril or losartan. The study also shows that antihypertensive treatment reduces microalbuminuria and decreases the progression of albuminuria even in normotensive patients.

This was a small study (100 subjects) done over a short follow-up period of 3 months duration. The two drug classes had an equivalent effect on the end point: Microalbuminuria reduction.

**Table 1: Microalbuminuria (mg/24 hrs urine) gender in the two groups.**

|        | At the start |          | End of 3 months |          |
|--------|--------------|----------|-----------------|----------|
|        | Male | Female | Total | Male | Female | Total |
| 1. Ramipril | 160  | 125  | 140 | 135  | 992  | 115  |
| N      | 24   | 26    | 50   | 25    | 25    | 50    |
| SD     | 60.1 | 96.9  | 81.8 | 56.1  | 82.8  | 73.3  |
| 2. Losartan | 176  | 112  | 145 | 114  | 99    | 107   |
| N      | 25   | 26    | 50   | 24    | 26    | 50    |
| SD     | 76.9 | 77.9  | 77.4 | 58.8  | 77.6  | 67.3  |
Table 2: Blood pressure and microalbuminuria in the two groups.

|                | Ramipril | Losartan | T value | P value |
|----------------|----------|----------|---------|---------|
| SBP            | Mean     | SD       | Mean    | SD      |
|                | 135      | 6.5      | 133     | 8.6     |
| SBP-3          | 121      | 5.6      | 121     | 7.0     |
| DBP            | 86       | 6.7      | 80      | 5.0     |
| DBP-3          | 77       | 5.0      | 76      | 3.8     |
| Microalbumin   | 140      | 81.8     | 145     | 77.4    |
| Microalbumin-3 | 115      | 73.3     | 107     | 67.3    |

Our data indicate that losartan is not inferior to ramipril in providing renoprotection in subjects with type 2 diabetes and early nephropathy. This result is consistent with the emerging data that support the clinical equivalence of ARB and ACE inhibitors in various conditions associated with high cardiovascular risk.8

CONCLUSION

This study shows that both ramipril (ACE inhibitor) and losartan (ARB) reduced urinary albumin excretion; the differences...
between the two treatment regimens are not significant. Losartan is not inferior to ramipril in providing renoprotection in subjects with type 2 diabetes and early nephropathy.

Losartan showed a significant reduction in systolic blood pressure, though not much reduction was seen with ramipril. Despite this, both drugs have shown a reduction in albuminuria which supports the fact that reduction in microalbuminuria is independent of the antihypertensive action of the ramipril or losartan.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53.
2. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
4. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-8.
5. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-9.
6. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-10.
7. Thurman JM, Schrier RW. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med. 2003;114:588-98.
8. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S. Angiotensin-receptor blockade versus converting – Enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-61.
9. Viberti G, Wheelon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672-8.
10. American diabetes association: nephropathy in diabetes (Position Statement). Diabetes Care. 2004;27 Suppl 1:S79-83.
11. Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. Q J Med. 2001;94:89-94.
12. Weinberg MS, Kaperonis N, Bakris GL. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep. 2003;5(5):418-25.

doi: 10.5455/2319-2003.ijbcp20140417
Cite this article as: Sudhakar A, Pasula S, Simpson GB. Efficacy of drugs in controlling microalbuminuria of diabetic nephropathy. Int J Basic Clin Pharmacol 2014;3:350-3.